BRPI0408767A - inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv - Google Patents

inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv

Info

Publication number
BRPI0408767A
BRPI0408767A BRPI0408767-4A BRPI0408767A BRPI0408767A BR PI0408767 A BRPI0408767 A BR PI0408767A BR PI0408767 A BRPI0408767 A BR PI0408767A BR PI0408767 A BRPI0408767 A BR PI0408767A
Authority
BR
Brazil
Prior art keywords
hiv
treatment
reverse transcriptase
formula
compounds
Prior art date
Application number
BRPI0408767-4A
Other languages
English (en)
Inventor
James Patrick Dunn
Steven Swallow
Zachary Kevin Sweeney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to BR122016023941-1A priority Critical patent/BR122016023941B1/pt
Publication of BRPI0408767A publication Critical patent/BRPI0408767A/pt
Publication of BRPI0408767B1 publication Critical patent/BRPI0408767B1/pt
Publication of BRPI0408767B8 publication Critical patent/BRPI0408767B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

"INIBIDORES DA TRANSCRIPTASE REVERSA NãO-NUCLEOSìDEOS I PARA O TRATAMENTO DE DOENçAS MEDIADAS PELO HIV". A presente invenção refere-se a novos compostos heterocíclicos de fórmula (I), em que R¬ 1¬-R¬ 4¬, X¬ 1¬ e X¬ 2¬ são como definidos no sumário e sais e solvatos farmaceuticamente aceitáveis destes, métodos para inibir ou modular a transcriptase reversa do Vírus da Imunodeficiência Humana (HIV) com compostos de fórmula (I), composições farmacêuticas contendo a fórmula I misturadas com pelo menos um solvente, veículo ou excipiente e processos para se preparar os compostos de fórmula I. O compostos são úteis para o tratamento de distúrbios, em que o HIV e os vírus geneticamente relacionados estão envolvidos.
BRPI0408767A 2003-03-24 2004-03-22 inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica BRPI0408767B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122016023941-1A BR122016023941B1 (pt) 2003-03-24 2004-03-22 Inibidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso e composição farmacêutica

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45713003P 2003-03-24 2003-03-24
US60/457,130 2003-03-24
PCT/EP2004/002995 WO2004085411A1 (en) 2003-03-24 2004-03-22 Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases

Publications (3)

Publication Number Publication Date
BRPI0408767A true BRPI0408767A (pt) 2006-03-28
BRPI0408767B1 BRPI0408767B1 (pt) 2017-10-31
BRPI0408767B8 BRPI0408767B8 (pt) 2021-05-25

Family

ID=33098199

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122016023941-1A BR122016023941B1 (pt) 2003-03-24 2004-03-22 Inibidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso e composição farmacêutica
BRPI0408767A BRPI0408767B8 (pt) 2003-03-24 2004-03-22 inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122016023941-1A BR122016023941B1 (pt) 2003-03-24 2004-03-22 Inibidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso e composição farmacêutica

Country Status (20)

Country Link
US (2) US7208509B2 (pt)
EP (1) EP1608633B1 (pt)
JP (1) JP4708329B2 (pt)
KR (1) KR101122456B1 (pt)
CN (1) CN100588650C (pt)
AR (1) AR043673A1 (pt)
AU (1) AU2004224153B2 (pt)
BR (2) BR122016023941B1 (pt)
CA (1) CA2518437C (pt)
CL (1) CL2004000590A1 (pt)
CO (1) CO5601029A2 (pt)
ES (1) ES2574580T3 (pt)
HR (1) HRP20050830A2 (pt)
IL (1) IL170343A (pt)
MX (1) MXPA05010210A (pt)
NO (1) NO334095B1 (pt)
NZ (1) NZ541829A (pt)
RU (1) RU2342367C2 (pt)
TW (1) TW200505441A (pt)
WO (1) WO2004085411A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005027677D1 (de) * 2004-04-01 2011-06-09 Aventis Pharma Inc 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
SG148179A1 (en) * 2004-07-27 2008-12-31 Hoffmann La Roche Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
EP1863777A1 (en) * 2005-03-24 2007-12-12 F.Hoffmann-La Roche Ag 1,2,4 -triazole-5-one compounds as heterocyclic reverse transcriptase inhibitors
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
JP2009510013A (ja) * 2005-09-30 2009-03-12 エフ．ホフマン−ラ ロシュ アーゲー Ｎｎｒｔ阻害剤
BRPI0617720A2 (pt) 2005-10-19 2011-08-02 Hoffmann La Roche compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
EP1963259B1 (en) * 2005-12-15 2012-02-15 AstraZeneca AB Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
PT2049506E (pt) 2006-07-07 2015-10-09 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
DK2057125T3 (da) 2006-08-16 2011-05-16 Hoffmann La Roche Ikke-nucleosid revers transkriptase-inhibitorer
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
BRPI0807581A2 (pt) * 2007-02-23 2014-07-01 Gilead Science, Inc. Moduladores de propriedades farmacocinéticas de produtos terapêuticos
AU2008235549A1 (en) * 2007-04-09 2008-10-16 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
ES2401037T3 (es) * 2007-05-30 2013-04-16 F. Hoffmann-La Roche Ag Procedimiento para la preparación de triazolonas
CN101679294B (zh) 2007-05-30 2012-08-08 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
WO2008157330A1 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
WO2008157273A1 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
BRPI0813404A2 (pt) * 2007-06-22 2014-12-30 Hoffmann La Roche Derivados de uréia e carbamato como inibidores de transcriptase reversa de não-nucleosídeo
US8492415B2 (en) * 2007-07-03 2013-07-23 Yale University Azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiviral therapy (HIV)
RU2495878C2 (ru) * 2007-12-21 2013-10-20 Ф.Хоффманн-Ля Рош Аг Гетероциклические антивирусные соединения
CN102971308B (zh) 2010-03-30 2015-02-04 默克加拿大有限公司 非核苷类逆转录酶抑制剂
CU23896B1 (es) * 2010-04-01 2013-05-31 Ct De Ingeniería Genética Y Biotecnología Método para inhibir la replicación del vih en células de mamíferos
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CN104230929B (zh) * 2013-06-19 2015-11-18 华东师范大学 一种非核苷类hiv-1反转录酶抑制剂
RU2693622C2 (ru) 2014-04-01 2019-07-03 Мерк Шарп И Доум Корп. Пролекарственные средства ингибиторов обратной транскриптазы вич
WO2026042788A1 (ja) * 2024-08-20 2026-02-26 塩野義製薬株式会社 複素環誘導体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274185A (en) 1963-10-08 1966-09-20 S E Massengill Company Phthalazine derivatives
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
JP2542880B2 (ja) 1986-12-19 1996-10-09 メレルダウファーマスーティカルズ インコーポレーテッド ５−アリ―ル−３ｈ−１，２，４，−トリアゾ―ル−３−オン類の抗痙攣剤としての用途
US5436252A (en) 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
JP2593084B2 (ja) 1986-12-19 1997-03-19 メレルダウファーマスーティカルズ インコーポレーテッド ５−アリールー３ｈ−１，２，４−トリアゾールー３−オン類の神経変性障害の処置への用途
US4826990A (en) 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US4942236A (en) 1987-09-30 1990-07-17 American Home Products Corporation 2-aryl substituted pyridyl-containing phenyl sulfonamido compounds as antiallergic and antiinflammatory agents
US5103014A (en) 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
US4966909A (en) 1989-12-20 1990-10-30 Merrell Dow Pharmaceuticals 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants
US5331002A (en) 1990-04-19 1994-07-19 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5641796A (en) 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
AU2381397A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
HU228960B1 (hu) * 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
UA82048C2 (uk) 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
JP2002275165A (ja) * 2001-01-12 2002-09-25 Sumitomo Pharmaceut Co Ltd トリアゾール誘導体

Also Published As

Publication number Publication date
IL170343A (en) 2014-03-31
BRPI0408767B8 (pt) 2021-05-25
EP1608633A1 (en) 2005-12-28
CO5601029A2 (es) 2006-01-31
NO20054264D0 (no) 2005-09-15
EP1608633B1 (en) 2016-04-20
KR101122456B1 (ko) 2012-04-26
RU2005132632A (ru) 2006-06-10
US7208509B2 (en) 2007-04-24
ES2574580T3 (es) 2016-06-20
AU2004224153B2 (en) 2009-04-02
BRPI0408767B1 (pt) 2017-10-31
NO20054264L (no) 2005-10-14
US7348345B2 (en) 2008-03-25
JP2006521319A (ja) 2006-09-21
WO2004085411A1 (en) 2004-10-07
US20040192704A1 (en) 2004-09-30
JP4708329B2 (ja) 2011-06-22
CL2004000590A1 (es) 2005-02-04
CN100588650C (zh) 2010-02-10
BR122016023941B1 (pt) 2021-10-13
AU2004224153A1 (en) 2004-10-07
KR20050115294A (ko) 2005-12-07
NO334095B1 (no) 2013-12-09
MXPA05010210A (es) 2005-11-23
HRP20050830A2 (en) 2006-09-30
AR043673A1 (es) 2005-08-03
CA2518437C (en) 2012-07-10
US20070179157A1 (en) 2007-08-02
CN1759104A (zh) 2006-04-12
RU2342367C2 (ru) 2008-12-27
CA2518437A1 (en) 2004-10-07
NZ541829A (en) 2008-11-28
TW200505441A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
BRPI0408767A (pt) inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv
BRPI0407591A (pt) inibidores de transcriptase reversa de não-nucleosìdeo
BRPI0408704A (pt) benzil-piridazinonas como inibidores de transcriptase reversa
BRPI0208811B8 (pt) derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
BRPI0415759A (pt) compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
BRPI0610030B8 (pt) Composto, composição farmacêutica, e, uso de um composto
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BRPI0516972A (pt) composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto
BR0209267A (pt) Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf)
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BRPI0512075A (pt) composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
BR0213967A (pt) Análogos de himbacina como antagonistas do receptor de trombina
BR0212008A (pt) Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste
BR0210350A (pt) Nucleosìdeos 4'-substituìdos
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
SE0402735D0 (sv) Novel compounds
BRPI0511982A (pt) compostos antiviróticos heterocìclicos
BR0314379A (pt) Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase
BR0308212A (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BRPI0513858A (pt) compostos de benziltriazolona como inibidores não-nucleosìdeos da transcriptase reversa
BR0315801A (pt) Compostos piridopirimidinona, eu processo de preparação e as composições farmacêuticas que os contêm

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/03/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.